Topic: Respiratory Illness
The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in the field.
ReViral has hit its primary and secondary endpoints in a small midstage trial testing its experimental med against RSV.
The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.
AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals.
ALung Technologies raised $36 million to trial its artificial lung technology for patients with respiratory failure.